Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Thomson Reuters Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Thomson Reuters Corp trades at $89.65 (market cap $38.95B). The key difference: Alnylam Pharmaceuticals, Inc. and Thomson Reuters Corp are close in size by market cap, and Thomson Reuters Corp pays a 2.92% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TRI | |
|---|---|---|
Market Cap | $39.89B | $38.95B |
Sector | Health | Industrials |
52-Week High | $491.22 | $214.21 |
52-Week Low | $278.09 | $76.55 |
Enterprise Value | $38.15B | $40.91B |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Thomson Reuters (TRI) trades at $89.65, up 0.92% today, with a bullish technical signal and strong support at $88. The company shows robust fundamentals with a 19.93% net income margin and consistent earnings beats, though Q4 2025 missed expectations. Recent AI partnerships and a special dividend highlight strategic moves, while cash flow turned negative in 2025 due to investing activities.
Outlook is positive with a consensus price target of $129.96, implying 45% upside, supported by 51.85% analyst buy ratings. Risks include AI implementation challenges and revenue volatility, but the stock's valuation at P/E 25.8 appears reasonable given growth prospects in legal and compliance sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
